Epix, Schering Get EU Vasovist OK
5th Oct 2005, 16:44 GMT
Epix Pharmaceuticals a developer of contrast agents used in diagnostic imaging, said that its worldwide marketing partner, German drug maker Schering AG, received European approval to sell the blood contrast agent Vasovist.
Epix, Schering Get EU Vasovist OK related news:
- EPIX Announces European Approval of Vasovist — Angiography/ Cardiac Cath News from StratCenter.com
- Schering erhält EU-Zulassung für "Vasovist" — Finanztreff.de / TOPTHEMEN
- Market Pulse: EPIX Pharma gets lift from Vasovist approval in Europe — Angiography/ Cardiac Cath News from StratCenter.com
- Schering AG Receives EU Approval for Novel Contrast Agent Vasovist — Angiography/ Cardiac Cath News from StratCenter.com
- Schering AG Receives EU Approval for Novel Contrast Agent Vasovist(R) — PR Newswire: All Releases
- Epix gets EU green light to sell imaging compound — bizjournals.com Health Care:Pharmaceuticals headlines
- European approval for Epix's vascular visualization drug — Pharmaceutical Business Review Online
- Schering buy — Finanztreff.de / ANALYSEN
- JNJ's Remicade Gets Expanded EU Approval — Pharmaceuticals News from StratCenter.com
- Schering AG's menopausal symptoms drug approved in US — Pharmaceutical Business Review Online
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris